Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies

Mise à jour : Il y a 4 ans
Référence : NCT02507479

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The study hypotheses is that the introduction of dose escalated thiotepa, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with lymphoid malignancies not eligible for standard transplantation.


Critère d'inclusion

  • non-Hodgkin Lymphoma,Hodgkin lymphoma,Chronic lymphocytic leukemia,Multiple myeloma

Liens